- The FDA has signed off Biomea Fusion Inc's BMEA Investigational New Drug application to begin a Phase 1 trial of BMF-219, a selective irreversible menin inhibitor.
- The trial will include adult patients with relapsed or refractory acute leukemia, including those with an MLL/KM2TA gene rearrangement or NPM1 mutation.
- The trial will assess the safety, pharmacokinetics (PK), and pharmacodynamic (PD) profile in adult patients.
- Related content: Benzinga's Full FDA Calendar.
- Price Action: BMEA shares were up 5.64% at $11.23 before the trading was halted during the market session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
